Engineered antibody fragments and the rise of single domains

By P. Holliger, P. Hudson. Nature Biotechnology, 2005

1,901 citations recorded by the source corpus.

Subfields: Molecular Biology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/8f617f88b9ea70408e09860482b1a3b68cdcdc44

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Radiology, Nuclear Medicine and Imaging

Citations in the corpus

Antibody targeted drugs as cancer therapeutics (2006, background): “The latter, however, are characterized by higher affinity and can mediate an additional effect through the Fc domai”
Electrochemical Biosensors - Sensor Principles and Architectures (2008, background): “Such small, recombinant antibody fragments can be linked to other molecules, for example lipids, drugs and proteins [227].”
Nanobodies: natural single-domain antibodies. (2013, background): “Nbs, the recombinant single variable domains derived from camelid HCAbs, are generally readily obtained after a brief immunization, followed by cloning the V gene repertoire from peripheral blood lymphocytes and by selection through phage display (58).”
Engineering novel binding proteins from nonimmunoglobulin domains (2005, background): “This has inspired many attempts to create alternative binding proteins, based either on scaffolds with the immunoglobulin fol”
Antibody-based therapies for malaria (2005, background): “As a result, at least 18 antibodies have approval for use from the US Food and Drug Administration, and at least 100 are in clinical trials worldwide, the majority for the treatment of cancer, transplant rejection or autoimmune diseas”
RosettaAntibodyDesign (RAbD): A general framework for computational antibody design (2017, neutral): “companies, government, and academia[1-7].”
Potent antibody therapeutics by design (2006, background): “In addition, antibody fragments are discussed, because their clinical importance is growin”
Properties, production, and applications of camelid single-domain antibody fragments (2007, background): “As compared to human VH domains, the VHH FRs show a high sequence homology of more than 80%, and their 3D structures can be superimposed (Muyldermans et al. 2001; Holliger and Hudson 2005).”
Therapeutic antibodies: successes, limitations and hopes for the future (2009, neutral): “Since then, several studies have demonstrated the possibility to develop human variable domains into stable dAbs (Holliger and Hudson, 2005).”
Phage-encoded combinatorial chemical libraries based on bicyclic peptides. (2009, methodology): “The approach is very powerful and has been used to fashion ligand binding sites in antibodie”